| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
LifeMD, Inc. Common Stock$3.68
-0.68 (-17.44%)
Market Cap
177.97 M
EPS
-0.20
P/E Ratio
-
Value Trade
3.26 M
SEC Financials
Q1 2026Dilution Risk
Revenue
50.16 M
Operating CF
444.62 K
Total Assets
70.12 M
Total Liabilities
55.09 M
Equity
15.04 M
1.1 %
Week
-25.05 %
1 Month
-30.17 %
3 Month
19.87 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
34.48 M
Monthly Burn
-
Runway
-
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
1.82 M
52 Week Range
2.56 - 7.32
% held by Insiders
18.06 %
% held by Institutions
44.1 %
Enterprise Value
143.50 M
Total Shares
48.37 M
Short %
17.98 %
Float Shares
39.71 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LFMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LFMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-LFMD
Aug 5, 2026▼ -17.4%today
LifeMD Reports Second Quarter 2026 Results
LifeMD reported its second quarter 2026 results, achieving revenues of $47.3 million, which fell within the company's guidance range. The company noted a significant transition from compounded to branded GLP-1 therapies, with gross margins improving to 89%. Despite an adjusted EBITDA loss of $3.5 million, LifeMD expects to return to profitability in the second half of 2026, driven by growth in active subscribers and strategic partnerships.
Read more →-LFMD
Jul 24, 2026LifeMD to Report Second Quarter 2026 Financial Results on August 5
LifeMD, Inc. will report its financial results for Q2 2026 on August 5, 2026, after market close. The company will also host a conference call at 4:30 p.m. ET to discuss these results. LifeMD specializes in virtual primary care services and has a comprehensive digital care platform.
Read more →-LFMD
Jun 22, 2026▼ -9.3%on this news
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
LifeMD has announced a strategic collaboration with Antares Pharma to launch a self-pay program for XYOSTED, a testosterone injection. Set to begin in July 2026, the program will be available in 37 states and aims to enhance access to treatment for hypogonadism. The initiative includes consumer education and a streamlined telehealth process for patients.
Read more →-LFMD
May 15, 2026LifeMD to Participate in Upcoming Investor Conferences
LifeMD, Inc. will participate in two upcoming investor conferences: the LD Micro Invitational XVI Conference and the B. Riley Securities 26th Annual Investor Conference. Management will present at both events and is available for one-on-one meetings with investors. This engagement reflects LifeMD's strategy to enhance investor relations and showcase its virtual primary care services.
Read more →-LFMD
May 7, 2026▼ -14.8%on this news
LifeMD Reports First Quarter 2026 Results
LifeMD, Inc. reported strong financial results for Q1 2026, with a record addition of over 42,000 telehealth subscribers, bringing the total to over 365,000. The company achieved revenue of $50.2 million, surpassing its guidance. Management expressed optimism about future growth driven by strategic partnerships and new product launches in health services.
Read more →-LFMD
May 6, 2026LifeMD Reports First Quarter 2026 Results First quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and in line, respectively, with the Company's guidance. Gross margin increased approxi
LifeMD reported its first quarter 2026 financial results, showcasing a revenue of $50.2 million, aligned with company guidance. The company achieved a 657% quarter-over-quarter growth in Women's Health patient signups and realized a gross margin of 88%. Despite the positive revenue and subscriber growth, the company also noted an adjusted EBITDA loss of $4.5 million. LifeMD continues to build its platform, focusing on expanding its subscriber base and enhancing service offerings.
Read more →-LFMD
Apr 27, 2026LifeMD to Report First Quarter 2026 Financial Results on May 6
LifeMD, Inc. (Nasdaq: LFMD) will report its financial results for Q1 2026 on May 6, 2026, after U.S. market close. A conference call will follow at 4:30 p.m. Eastern time. LifeMD specializes in virtual primary care, providing telemedicine and access to various health services.
Read more →-LFMD
Mar 16, 2026▲ +10.6%on this news
LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
LifeMD, Inc. has announced the appointment of Atul Kavthekar as Chief Financial Officer as part of its leadership expansion aimed at supporting growth. Kavthekar, a seasoned executive with nearly 30 years of experience in healthcare finance, will focus on strengthening the company’s financial strategy and operational infrastructure. Additionally, Chris Pisano has been appointed as Chief Marketing Officer, and Jessica Friedeman will take on the role of Chief Business Officer. These appointments reflect LifeMD's commitment to innovation and AI-driven healthcare delivery.
Read more →-LFMD
Mar 9, 2026LifeMD Reports Fourth Quarter and Full Year 2025 Results Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITD
LifeMD, Inc. reported strong financial results for the fourth quarter and full year 2025, with a revenue increase of 25% year-over-year to $194.1 million and adjusted EBITDA surging 309% to $15.3 million. The company successfully launched oral Wegovy, achieving notable patient sign-ups in weight management. Despite exiting with a solid cash position and no debt, LifeMD anticipates a short-term EBITDA loss in Q1 2026 due to strategic investments in patient acquisition. Overall, the company remains optimistic about future growth opportunities in the telehealth sector.
Read more →-LFMD
Feb 23, 2026▼ -6.4%on this news
LifeMD to Report Fourth Quarter 2025 Financial Results on March 9
LifeMD, Inc. will report its financial results for Q4 2025 on March 9, 2026, after market close. The company will also host a conference call at 4:30 p.m. Eastern time to discuss these results. LifeMD specializes in virtual primary care and offers various telemedicine services.
Read more →-LFMD
Jan 6, 2026▲ +7.9%on this news
LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank
LifeMD has announced the closing of a $50 million revolving credit facility with Citizens Bank, which features a maturity date of January 2, 2029. The facility provides $30 million of committed availability and an additional accordion option of up to $20 million. CFO Marc Benathen expressed confidence in the company's financial health, stating that the existing cash flow is sufficient for growth initiatives. The facility is competitively priced and offers significant financial flexibility for potential corporate development.
Read more →-LFMD
Jan 5, 2026▲ +12%on this newsshared move
LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill
LifeMD has expanded its collaboration with Novo Nordisk to offer the newly FDA-approved Wegovy® pill, the first oral GLP-1 therapy for chronic weight management. This partnership allows eligible patients to access the medication through LifeMD's telehealth platform at competitive prices. The initiative aims to enhance patient access to effective obesity treatments and streamline the healthcare experience.
Read more →-LFMD
Dec 26, 2025▼ -12.5%on this news
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD, Inc. has announced a cash dividend of $0.5546875 per share on its Series A Cumulative Perpetual Preferred Stock. The dividend will be paid on January 15, 2026, to shareholders on record by January 5, 2026. This announcement highlights LifeMD's ongoing financial health and commitment to its investors.
Read more →-LFMD
Nov 17, 2025LifeMD Reports Third Quarter 2025 Results Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million. Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted
LifeMD, a provider of virtual primary care services, reported its third-quarter 2025 results, showing a revenue increase of 13% year-over-year, totaling $60.2 million. The company has successfully improved its adjusted EBITDA by 20%, reaching $5.1 million, and reported growth in telehealth revenue at 18%. However, challenges in the weight management market and a net loss of $4.6 million were noted. The firm also divested its majority stake in WorkSimpli and is positioned to expand its telehealth and pharmacy services significantly in the coming year.
Read more →-LFMD
Nov 5, 2025LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
LifeMD, Inc. has announced the rescheduling of its third quarter 2025 earnings release to November 17, 2025, due to corrections in revenue recognition from previous periods. The adjustments, totaling approximately $4.6 million, are not expected to materially impact the company's cash flow. The company also plans to file a Form 12b-25 informing the SEC of the late filing. Despite the errors, LifeMD assures that the revisions will not significantly alter revenue results compared to prior guidance.
Read more →-LFMD
Nov 4, 2025▼ -5.6%on this newsshared move
LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform Transaction Values WorkSimpli at $65 Million Enterprise Value; Support's LifeMD's Strategic F
LifeMD, Inc. (Nasdaq: LFMD) has divested its majority ownership interest in WorkSimpli Software LLC for approximately $65 million, indicating a strategic shift towards focusing on virtual healthcare services and pharmacy offerings. The transaction, which closed on November 4, 2025, provided LifeMD with approximately $22 million in cash at closing, with potential for an additional $28 million based on WorkSimpli achieving future targets. This move is seen as a key milestone for LifeMD, allowing it to concentrate on expanding its core virtual care technologies and diversifying into new medical areas, while WorkSimpli enters a new phase of independence and growth.
Read more →-LFMD
Aug 5, 2025LifeMD Reports Second Quarter 2025 Results Total revenue increased 23% year-over-year to $62.2 million; adjusted EBITDA rose 223% to $7.1 million Telehealth revenue increased 30% to $48.6 million; telehealth adjusted EBI
LifeMD, Inc. reported strong second quarter results for 2025, showing a 23% increase in total revenue to $62.2 million and an impressive 223% growth in adjusted EBITDA, reaching $7.1 million. The company significantly boosted its telehealth revenue by 30%, driven by a rise in active subscribers. Additionally, LifeMD expanded its service offerings into behavioral and women's health, enhancing its virtual care platform. Despite some financial challenges, including a net loss, the company fully repaid all senior debt, leading to a firm balance sheet position.
Read more →-LFMD
Jul 31, 2025LifeMD Names COO and Promotes Two Executives
LifeMD, Inc. has announced the appointment of Shayna Webb Dray as its new Chief Operating Officer, reflecting the company's commitment to strong leadership in its operations. Webb Dray, who has been instrumental in LifeMD's growth since 2021, is expected to play a significant role in expanding the company's verticals and improving patient care quality. In addition, Jessica Friedeman and Jacob Ellison have been promoted within the company, reinforcing LifeMD's strategy to leverage internal talent for continued innovation and operational success.
Read more →-LFMD
May 6, 2025LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70% Adjusted EBITDA increased to $8.7 million from $0.1
LifeMD, Inc. reported strong financial results for the first quarter of 2025, with total revenues rising 49% year-over-year to $65.7 million and telehealth revenue increasing 70%. The company achieved its first GAAP net income of $0.6 million, translating to positive EPS for the first time. Adjusted EBITDA also saw a significant leap, reaching $8.7 million compared to only $0.1 million a year prior. In light of this performance, LifeMD has raised its full-year guidance for total revenues and adjusted EBITDA.
Read more →-LFMD
Mar 10, 2025▼ -8.6%on this news· ran to +21% by day 3
LifeMD Reports Fourth Quarter 2024 Results Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60% Adjusted EBITDA increased 78% to $9.0 million Telehealth adjusted EBITDA incre
LifeMD, Inc. reported strong financial results for the fourth quarter of 2024, with consolidated revenues of $64.3 million marking a 43% increase year-over-year. The company's telehealth segment also performed well, demonstrating a 60% revenue growth and a significant jump in adjusted EBITDA, which rose by 396%. Looking ahead, LifeMD projects 2025 revenues between $265 million and $275 million, alongside substantial EBITDA growth, reflecting optimistic prospects in the telehealth market. Moreover, the organization is set to utilize its strong cash reserves to enhance its offerings and market reach.
Read more →-LFMD
Apr 29, 2024LifeMD Appoints Dr. Calum MacRae to its Board of Directors
LifeMD, Inc. has appointed Dr. Calum MacRae, a respected clinician and researcher from Harvard Medical School, to its Board of Directors. Dr. MacRae's extensive background in cardiology and clinical innovation aligns with LifeMD's focus on enhancing virtual healthcare services. His experience with chronic disease management and technology integration is anticipated to significantly contribute to the company's ongoing development and expansion of services.
Read more →-LFMD
Dec 13, 2023▼ -6.4%on this news
LifeMD and Medifast Partner to Offer Transformative Weight Management Solution Collaboration will integrate LifeMD's telehealth platform and GLP-1 offering for medically qualified patients with OPTA VIA Coach-guided, hea
LifeMD, a provider of virtual primary care services, has partnered with Medifast to offer a comprehensive weight management solution. This collaboration will integrate LifeMD's telehealth platform with Medifast's OPTAVIA coaching system, allowing clients to access clinically supported weight loss programs, including GLP-1 medications. The partnership aims to address the public health crisis of obesity and is backed by a $20 million investment from Medifast, emphasizing their commitment to enhancing weight management services. Both companies bring extensive expertise and a strong client base to the initiative, positioning them well in the growing health and wellness market.
Read more →-LFMD
Jun 20, 2023▲ +5.6%on this news· ran to +16% by day 3
LifeMD Appoints William J. Febbo to its Board of Directors
LifeMD, Inc. has appointed William J. Febbo to its Board of Directors. Febbo, who is currently the CEO of OptimizeRx Corporation, is expected to contribute significantly to LifeMD's mission of enhancing virtual primary care services. With over 25 years of experience in healthcare and technology, his insights into patient engagement and digital optimization are anticipated to aid the company's growth and development. Febbo expressed his commitment to improving healthcare access and affordability through collaboration with LifeMD's leadership.
Read more →-LFMD
Mar 22, 2023▲ +19.7%on this news
LifeMD, Inc. Announces Closing of New $40 Million Credit Facility
LifeMD, Inc. has successfully closed a $40 million senior secured credit facility with Avenue Capital, which matures on October 1, 2026. This financing consists of an initial $15 million term loan, with provisions for additional capital in the future. Management expresses confidence that this funding will enhance the company's financial flexibility and support their strategic growth initiatives. The credit facility is secured by a lien on most of the company's assets and includes an 18-month interest-only period.
Read more →-LFMD
Feb 10, 2023LifeMD Appoints Dr. Joan LaRovere to its Board of Directors
LifeMD has appointed Dr. Joan LaRovere to its Board of Directors, enlarging the board to nine members, seven of whom are independent. Dr. LaRovere brings significant clinical experience, having worked at top hospitals and contributing to healthcare innovations. Her expertise in analytics and technology is expected to enhance LifeMD's mission of providing accessible virtual healthcare services. The company focuses on leveraging technology to improve patient care access.
Read more →-LFMD
Sep 20, 2022LifeMD Appoints Bobby Jindal to the Board of Directors
Appoints Bobby Jindal to the Board of Directors YORK, September 20, 2022 - LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, is pleased to announce its appointment of Bobby Jindal, the 55th Governor of the State of Louisiana, to its board of director
Read more →-LFMD
Jan 19, 2022LifeMD Provides Initial FY2022 Guidance and Announces Preliminary FY2021 Revenues Total FY2022 revenue anticipated to be in the range of $142 to $148 million Remains on track to achieve Adjusted EBITDA profitability by Q
Provides Initial FY2022 Guidance and Announces Preliminary FY2022 revenue anticipated to be in the range of $142 to $148 million on track to achieve Adjusted EBITDA profitability by Q4 2022 preliminary fourth quarter revenue of $27.4 million and FY2021 consolidated revenue of
Read more →-LFMD
Sep 28, 2021LifeMD Announces Launch of Public Offering of Common Stock
Announces Launch of Public Offering of Common Stock YORK, September 28, 2021 - LifeMD, Inc. (the "Company") (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that it has commenced an underwritten registered public offering of shares of its common s
Read more →-LFMD
Sep 13, 2021LifeMD Appoints Seasoned Investor Naveen Bhatia to Board of Directors Industry veteran brings deep financial and management expertise to LifeMD as company continues to transform healthcare and build out growing telehealt
Appoints Seasoned Investor Naveen Bhatia to veteran brings deep financial and management expertise to LifeMD as continues to transform healthcare and build out growing telehealth platform YORK, September 13, 2021 - LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient teleh
Read more →-LFMD
Jul 15, 2021LifeMD Teams with a Leading Provider of Diagnostic Services and Axle Health to Deliver Telehealth Access to At-Home Diagnostics Patients Gain Access to Comprehensive Suite of Laboratory and Diagnostic Services at Preferr
Teams with a Leading Provider of Diagnostic Services and Axle Health to Deliver Telehealth Access to At-Home Diagnostics Gain Access to Comprehensive Suite of Laboratory and Diagnostic Services at Preferred Pricing, Performed in the Comfort and Convenience - LifeMD, Inc. (NASDA
Read more →-LFMD
Jun 11, 2021LifeMD Names Experienced Pharma Executive Alexander Mironov as President A seasoned industry veteran, Mr. Mironov has led transformational M&A and business development transactions in pharma and healthcare, totaling over
Names Experienced Pharma Executive Alexander Mironov as President seasoned industry veteran, Mr. Mironov has led transformational M&A and business development transactions in pharma and healthcare, totaling over $5 billion vision of disrupting healthcare delivery and services
Read more →-LFMD
Jun 3, 2021LifeMD TM Completes $15M Debt Financing Financing significantly bolsters liquidity position to support continued investment in growth of telehealth business
Completes $15M Debt Financing significantly bolsters liquidity position to support continued investment in growth of telehealth business YORK, June 3, 2021 - Inc. ("the Company") (NASDAQ: LFMD), a leading direct-to-patient telehealth company, announced today that it has succe
Read more →-LFMD
May 28, 2021Plaintiffs in Shareholder Suits Drop Claims Against LifeMD Cases voluntarily dismissed; company remains focused on growth, increasing access to healthcare via telemedicine.
in Shareholder Suits Drop Claims Against LifeMD voluntarily dismissed; company remains focused on growth, increasing access to healthcare via telemedicine. YORK, May 28, 2021 - LifeMD, Inc. ("the Company") (NASDAQ: LFMD), a leading direct-to-patient telehealth company, announc
Read more →-LFMD
May 18, 2021Star Actresses Kate del Castillo and Bellamy Young Partner With LifeMD as Brand Ambassadors For Shapiro MD The partnerships introduce celebrity influencers and their successful results using Shapiro MD TM hair loss treat
Star Actresses Kate del Castillo and Bellamy Young Partner With LifeMD as Brand Ambassadors For Shapiro MD The partnerships introduce celebrity influencers and their successful results using Shapiro MDTM hair loss treatment solutions to a large and global following YORK, May
Read more →-LFMD
May 13, 2021LifeMD Reports Q1 2021 Revenue up 323% to Record $18.2M, Raises Full Year Revenue Guidance to $90-$100M 92% of Q1 2021 revenue was generated by subscriptions, up from 75% in Q1 2020 Total patients and customers served na
Reports Q1 2021 Revenue up 323% to Record $18.2M, Raises Full Year Revenue Guidance to $90-$100M 92% of Q1 2021 revenue was generated by subscriptions, up from 75% in Q1 2020 Total patients and customers served nationwide surpassed 320,000 Gross Margins of 82%, up 13% from
Read more →-LFMD
Apr 19, 2021LifeMD Announces Expected Record Revenue of $18.2M for Q1'21, Up 323% Vs. Q1'20, Due to Growth in Subscriptions and Patient Acquisition Exceeds Initial Guidance Due to Stronger Than Expected March; 41% Growth Vs. Q4'20
Announces Expected Record Revenue of $18.2M for Q1'21, Up 323% Vs. Q1'20, Due to Growth in Subscriptions and Patient Acquisition Initial Guidance Due to Stronger Than Expected March; 41% Growth Vs. Q4'20 YORK, April 19, 2021 - LifeMD, Inc. ("the Company") (NASDAQ: LFMD), a lead
Read more →-LFMD
Apr 16, 2021Short-Seller's Note is Short on Credibility, LifeMD Says Company cites errors, distortions in anonymous "note" intended to hammer stock for quick profit
Note is Short on Credibility, LifeMD Says cites errors, distortions in anonymous "note" intended to hammer stock for quick profit YORK, April 16, 2021 - LifeMD, Inc. ("the Company") (NASDAQ: LFMD), a leading direct-to-patient telehealth company, released a letter to sharehold
Read more →-LFMD
Apr 15, 2021LifeMD Responds to Anonymous Short "Report"
Responds to Anonymous Short "Report" YORK, NY, April 15, 2021 - LifeMD, Inc. ("the Company") (NASDAQ: LFMD) is a leading direct-to-patient telehealth an unsigned note making false claims against LifeMD and its present and former officers was posted on the website of a purporte
Read more →-LFMD
Feb 22, 2021Conversion Labs Begins Trading Under New Company Name, LifeMD, and Ticker Symbol
Labs Begins Trading Under New Company Name, LifeMD, and Ticker Symbol, LFMD YORK, NY, February 22, 2021 - Conversion Labs, Inc. (NASDAQ: CVLB) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, will begin trading at the opening of the market today under its new nam
Read more →-LFMD
Feb 12, 2021Conversion Labs to Become Life MD with Launch of New Concierge Telehealth Services Company Completes $14 Million Unregistered Private Placement with Strategic Institutional Investors to Support Nationwide Launch of New T
Labs to Become Life MD with Launch of New Concierge Telehealth Services Completes $14 Million Unregistered Private Placement with Strategic Institutional Investors to Support Nationwide Launch of New Telehealth Service Offerings YORK, NY, February 12, 2021 - Conversion Labs, I
Read more →-LFMD
Feb 5, 2021Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer
Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) - Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial o
Read more →-LFMD
Jan 19, 2021Conversion Labs Expects 2020 Revenue up 205% to Record $38.0 Million, Subscription ARR up 525% to $26.0 Million
Labs Expects 2020 Revenue up 205% to Record $38.0 Million, Subscription ARR up 525% to $26.0 Million YORK, NY, January 19, 2021 - Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, reported preliminary unaudited results for its fourth quart
Read more →-LFMD
Jan 11, 2021Conversion Labs Appoints Leading Telehealth Professional, Dr. Anthony Puopolo, as Chief Medical Officer PUBLISHED JAN 11, 2021 8:31
Labs Appoints Leading Telehealth Professional, Dr. Anthony Puopolo, as Chief Medical Officer 11, 2021 8:31 AM EST YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) - Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed licensed personal care and we
Read more →-LFMD
Jan 5, 2021Conversion Labs Appoints Digital Marketing Executive, Bryant Hussey, as Chief Digital Officer PUBLISHED JAN 5, 2021 10:15AM
Labs Appoints Digital Marketing Executive, Bryant Hussey, as Chief Digital Officer YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) - Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed digital marketing expert and industry thought-leader, Bryant
Read more →-LFMD
Nov 20, 2020Conversion Labs Appoints Expert Life Sciences Attorney, Eric H. Yecies, as Chief Compliance Officer and General Counsel
Labs Appoints Expert Life Sciences Attorney, Eric H. Yecies, as Chief Compliance Officer and General Counsel YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has appointed expert Life Sciences a
Read more →-LFMD
Nov 17, 2020Conversion Labs, Inc. Condensed Consolidated Balance Sheet (Unaudited)
Consolidated Balance Sheet September 30, 2020 Pro Forma Adjustments Pro Forma September 30, 2020 ASSETS Current Assets Cash $ 916,637 $ 14,461,513 (1) $ 15,378,150 Accounts receivable, net 414,342 - 414,342 Product deposit 1,093,388 -
Read more →-LFMD
Nov 10, 2020Conversion Labs Appoints WEX CFO and Former Revlon CFO, Roberto Simon, to Board of Directors New York, NY
Labs Appoints WEX CFO and Former Revlon CFO, Roberto Simon, to Board of Directors York, NY, November 10, 2020 - Inc. (OTCQB: CVLB) (OTCQB: CVLBD), a direct-to-consumer telemedicine and wellness company, has appointed Roberto Simon to its board of directors and as the chair of
Read more →-LFMD
Nov 4, 2020Conversion Labs Closes Initial Round of $15 Million Private Placement with Institutional Investors, Advances Toward Nasdaq Uplisting
Labs Closes Initial Round of $15 Million Private Placement with Institutional Investors, Advances Toward Nasdaq Uplisting YORK, NY, November 4, 2020 - Conversion Labs, Inc. (OTCQB: CVLB) (OTCQB: CVLBD), a direct-to-consumer telemedicine and wellness company, has closed on appro
Read more →-LFMD
Oct 21, 2020Conversion Labs Appoints Former White House Physician and U.S. Navy Rear Admiral, Dr. Connie Mariano, to Board of Directors
Labs Appoints Former White House Physician and U.S. Navy Rear Admiral, Dr. Connie Mariano, to Board of Directors YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) - Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has appointed healthcare veteran,
Read more →-LFMD
Jun 11, 2019Conversion Labs Strengthens Board of Directors with Appointment of Two New Directors
Conversion Labs Strengthens Board of Directors with Appointment of Two New Directors NEW YORK, June 11, 2019 -- Conversion Labs, Inc. (OTCQB:CVLB) (the "Company" or "Conversion Labs"), an e-commerce company that builds proprietary consumer products and software brands, today
Read more →-LFMD
Oct 29, 2018Conversion Labs Announces Sean Fitzpatrick as Chief Acquisition Officer
Labs Announces Sean Fitzpatrick as Chief Acquisition Officer YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB) (the "Company"), an e-commerce company that builds and scales innovative brands, today announced the appointment of seasoned direct response
Read more →-LFMD
Jun 19, 2018IMMUDYNE, INC. Q2 2018 CORPORATE PRESENTATION PLEASE NOTE: OUR NAME WILL BE CHANGING TO CONVERSION LABS, INC. AS OF 7/1/2018 Immudyne, Inc. Q2 2018 Corporate presentation Ticker: IMMD Statements in this presentation that
IMMUDYNE, INC. Q2 2018 CORPORATE PRESENTATION PLEASE NOTE: OUR NAME WILL BE CHANGING TO CONVERSION LABS, INC. AS OF 7/1/2018 Immudyne, Inc. Q2 2018 Corporate presentation Ticker: IMMD Statements in this presentation that are not descriptions of historical facts are forward - loo
Read more →-LFMD
Jan 30, 2018ImmuDyne Announces Management Changes & Sale of Legacy Manufacturing Business New York, N.Y.
ImmuDyne Announces Management Changes & Sale of Legacy Manufacturing Business New York, N.Y., January 30, 2018 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) ("Immudyne" or the "Company"), a leader in the development and online marketing of OTC health and wellness products a
Read more →-LFMD
Mar 6, 2017Immudyne Provides 2017 Business Outlook
Provides 2017 Business Outlook KISCO, N.Y., March 06, 2017 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) ("Immudyne" or the "Company"), a leader in the development and marketing of OTC health and wellness products addressing large unmet needs, today issued its 2017 business
Read more →-LFMD
Oct 12, 2016Investor Presentation Q4 2016 (OTCQB: IMMD) www.immudyne.com Statements in this presentation that are not descriptions of historical facts are forward - looking statements relating to future events, and as such all forwa
Investor Presentation Q4 2016 (OTCQB: IMMD) www.immudyne.com Statements in this presentation that are not descriptions of historical facts are forward - looking statements relating to future events, and as such all forward - looking statements are made pursuant to the Securities
Read more →-LFMD
Aug 15, 2016ImmuDyne Announces Q2 2016 Net Sales Up 343%, Adjusted Non-GAAP Net Income
Announces Q2 2016 Net Sales Up 343%, Adjusted Non-GAAP Net Income KISCO, N.Y., August 15, 2016 (GLOBE NEWSWIRE) -- ImmuDyne (OTCQB:IMMD) announced today its financial results for the quarter ended June 30, 2016 and provided an update on its interim results for the first six wee
Read more →-LFMD
May 17, 2016ImmuDyne Announces Q1 2016 Net Sales Up 470%, Q2 Changes to Drive Growth, Profitability ImmuDyne (OTCQB:IMMD) announced today its financial results for the quarter ended
Announces Q1 2016 Net Sales Up 470%, Q2 Changes to Drive Growth, Profitability (OTCQB:IMMD) announced today its financial results for the quarter ended March 31, 2016 and provided an update on its interim results for the first six weeks of Q2 2016. for the three months ended M
Read more →-LFMD
Mar 7, 2016ImmuDyne Pre-Announces Full Year 2015 Revenues Up 73%; Guides for $10M in Fiscal 2016 Fiscal 2015 Revenues Expected To Be Up 73% to $1.225 Million, Compared to Fiscal 2014 Projecting $10 Million in Revenues for Fiscal 20
Pre-Announces Full Year 2015 Revenues Up 73%; Guides for $10M in Fiscal 2016 Fiscal 2015 Revenues Expected To Be Up 73% to $1.225 Million, Compared to Fiscal 2014 Projecting $10 Million in Revenues for Fiscal 2016 Focused on Cost Management and Profitability in Fiscal 2016
Read more →-LFMD
Apr 18, 2013IMMUDYNE Corporate Presentation
IMMUDYNE Corporate Presentation April 18, 2013 Disclaimer This Presentation includes and is based, inter alia, on forward - looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. These statements and this Present
Read more →Competitive Position
How LFMD ranks across every disease it competes inCompetitive Position is a premium feature
See how LFMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial